IL125379A - 19-nor-pregnene derivatives - Google Patents

19-nor-pregnene derivatives

Info

Publication number
IL125379A
IL125379A IL12537997A IL12537997A IL125379A IL 125379 A IL125379 A IL 125379A IL 12537997 A IL12537997 A IL 12537997A IL 12537997 A IL12537997 A IL 12537997A IL 125379 A IL125379 A IL 125379A
Authority
IL
Israel
Prior art keywords
pregnene derivatives
pregnene
derivatives
Prior art date
Application number
IL12537997A
Other languages
English (en)
Other versions
IL125379A0 (en
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of IL125379A0 publication Critical patent/IL125379A0/xx
Publication of IL125379A publication Critical patent/IL125379A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12537997A 1996-01-22 1997-01-17 19-nor-pregnene derivatives IL125379A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives
PCT/EP1997/000357 WO1997027210A1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives

Publications (2)

Publication Number Publication Date
IL125379A0 IL125379A0 (en) 1999-03-12
IL125379A true IL125379A (en) 2003-05-29

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12537997A IL125379A (en) 1996-01-22 1997-01-17 19-nor-pregnene derivatives

Country Status (36)

Country Link
US (1) US6180803B1 (zh)
EP (2) EP0785212A1 (zh)
JP (2) JP4368945B2 (zh)
KR (1) KR100396902B1 (zh)
CN (1) CN1187366C (zh)
AP (1) AP1176A (zh)
AR (1) AR005500A1 (zh)
AT (1) ATE184015T1 (zh)
BR (1) BR9707064A (zh)
CA (1) CA2243504C (zh)
CO (1) CO4810230A1 (zh)
CZ (1) CZ292047B6 (zh)
DE (1) DE69700470T2 (zh)
DZ (1) DZ2169A1 (zh)
EE (1) EE03692B1 (zh)
ES (1) ES2140961T3 (zh)
GR (1) GR3031954T3 (zh)
HK (1) HK1018216A1 (zh)
HU (1) HU221796B1 (zh)
ID (1) ID15840A (zh)
IL (1) IL125379A (zh)
IS (1) IS1902B (zh)
JO (1) JO1971B1 (zh)
MY (1) MY116845A (zh)
NO (1) NO309572B1 (zh)
NZ (1) NZ330954A (zh)
OA (1) OA10813A (zh)
PE (1) PE55998A1 (zh)
PL (1) PL185608B1 (zh)
RU (1) RU2166509C2 (zh)
SI (1) SI0886645T1 (zh)
TN (1) TNSN97015A1 (zh)
TR (1) TR199801399T2 (zh)
TW (1) TW411345B (zh)
WO (1) WO1997027210A1 (zh)
ZA (1) ZA97521B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
KR100856523B1 (ko) 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
WO2005020880A2 (en) * 2003-09-03 2005-03-10 Miscon Trading S.A. Methods for the treatment of endometriosis
JP5619337B2 (ja) 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109481450B (zh) * 2015-09-02 2021-07-23 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
AP1176A (en) 2003-06-30
PL327998A1 (en) 1999-01-04
TR199801399T2 (xx) 1998-10-21
EP0886645A1 (en) 1998-12-30
IS4800A (is) 1998-07-21
GR3031954T3 (en) 2000-03-31
TW411345B (en) 2000-11-11
KR100396902B1 (ko) 2004-05-03
JP4368945B2 (ja) 2009-11-18
IL125379A0 (en) 1999-03-12
ES2140961T3 (es) 2000-03-01
RU2166509C2 (ru) 2001-05-10
PE55998A1 (es) 1998-10-01
CA2243504C (en) 2004-03-30
JP2000503980A (ja) 2000-04-04
CZ230798A3 (cs) 1998-11-11
ZA97521B (en) 1997-08-04
AP9801299A0 (en) 1998-09-30
CZ292047B6 (cs) 2003-07-16
AU1595597A (en) 1997-08-20
AU708135B2 (en) 1999-07-29
HUP9900684A2 (hu) 1999-07-28
JP2009167188A (ja) 2009-07-30
CN1209811A (zh) 1999-03-03
EE9800219A (xx) 1998-12-15
NO983356L (no) 1998-07-21
AR005500A1 (es) 1999-06-23
WO1997027210A1 (en) 1997-07-31
CA2243504A1 (en) 1997-07-31
CO4810230A1 (es) 1999-06-30
NO983356D0 (no) 1998-07-21
DE69700470D1 (de) 1999-10-07
JO1971B1 (en) 1997-12-15
HUP9900684A3 (en) 1999-11-29
OA10813A (en) 2003-01-28
NZ330954A (en) 1998-10-28
KR19990081895A (ko) 1999-11-15
HU221796B1 (hu) 2003-01-28
CN1187366C (zh) 2005-02-02
SI0886645T1 (en) 1999-12-31
PL185608B1 (pl) 2003-06-30
TNSN97015A1 (fr) 2005-03-15
HK1018216A1 (en) 1999-12-17
MY116845A (en) 2004-04-30
ID15840A (id) 1997-08-14
US6180803B1 (en) 2001-01-30
EP0886645B1 (en) 1999-09-01
ATE184015T1 (de) 1999-09-15
DE69700470T2 (de) 2000-03-30
EE03692B1 (et) 2002-04-15
DZ2169A1 (fr) 2002-12-25
NO309572B1 (no) 2001-02-19
BR9707064A (pt) 1999-12-28
IS1902B (is) 2003-11-20
EP0785212A1 (en) 1997-07-23

Similar Documents

Publication Publication Date Title
HRP970174B1 (en) 6-phenylpyridil-2-amine derivatives
HU9700358D0 (en) New oxazolidinon derivatives
ZA9710906B (en) 6-Phenylpyridyl-2-amine derivatives
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
NZ330954A (en) 19-nor-pregnene derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
GB9702194D0 (en) Sulphonide derivatives
IL125226A0 (en) Heterocycle-condensed morphinoid derivatives (II)
HUP9902993A3 (en) Alkylaminobenzothiazole and -benzoxazole derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
PL334558A1 (en) Cephalosporinic derivatives
HU9701479D0 (en) N-benzylazolium derivatives
GB2321457B (en) 5-Aroylnaphthalene derivatives
GB9604996D0 (en) Benzodiazonine derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
GB9600063D0 (en) Guaridine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
IL125974A0 (en) 2-thioxotetrahydropyrimidin-4-one derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
SG67992A1 (en) N-benzylazolium derivatives
IL145864A0 (en) Benzothiophenecarboxamide derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees